October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
July 2024 in “Journal of Investigative Dermatology” JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
Four natural compounds were found to promote hair growth effectively.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
January 2026 in “Medicine” Hejie Shengfa Decoction may help treat alopecia areata by promoting hair growth and reducing inflammation, but more safety studies are needed.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
13 citations
,
September 2022 in “Frontiers in immunology” Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
March 2025 in “Experimental Dermatology” Overexpression of IKZF1 and Ikaros causes hair loss in mice similar to alopecia areata.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Too much IKZF1 and Ikaros protein may cause alopecia areata.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.